Expertise in
1
conditions

Sebastian A. Nunez

B, AR 
Expertise in
1
conditions
B, AR 

Overview

Sebastian Nunez practices practicing medicine in Argentina.

Mr. Nunez is highly rated in 1 condition, according to our data. His clinical expertise encompasses COVID-19, Multiple Sclerosis (MS), Severe Acute Respiratory Syndrome (SARS), and Parainfluenza.

He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

B, Argentina
Other Locations
La Plata, B, Argentina
Buenos Aires, C, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Biological
Study Drug: GSK3810109A
Study Phase: Phase 2
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
View 1 Less Clinical Trial

17 Total Publications

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 03, 2026

Frequently Asked Questions about Sebastian A. Nunez

Is Sebastian A. Nunez a top-rated expert for COVID-19?

MediFind is an objective health platform that identifies experts based on real-world data. Sebastian A. Nunez is classified as an Advanced expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sebastian A. Nunez participate in research or clinical trials?

Yes. Sebastian A. Nunez has published 17 articles and abstracts on conditions like COVID-19. You can view a list of Sebastian A. Nunez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nunez's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile